Expanded Canadian approval for Qiagen's HPV test
This article was originally published in Clinica
Executive Summary
The digene human papillomavirus (HPV) test platform developed by Qiagen may now be used in Canada to screen women for cervical cancer, with or without the Pap smear test. The digene HC2 High-Risk HPV DNA test was previously approved in Canada for co-testing with the Pap test; this label update now enables primary, front-line HPV screening. Health Canada has also approved updated labelling for the Venlo, Netherlands-based firm's HPV test, expanding approval to cover screening BD SurePath specimens. Testing with Qiagen's digene HPV Test can now be performed in labs on three different specimen collection vials: BD SurePath, Hologic PreservCty and Qiagen's digene Specimen Transport Medium.
You may also be interested in...
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.